Novyy klass antidiabeticheskikh preparatov - ingibitory natriy-glyukoznykh kotransporterov


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article considers the properties of canagliflozin and dapagliflozin, the first representatives of a new class of antidiabetic drugs: oral sodium - glucose cotransporter type 2 inhibitors (SGLT2), recently approved for use in the U.S. and Europe, respectively. SGLT2 inhibitors decrease blood glucose level by insulin-independent reduction of glucose reabsorption in the proximal renal tubuli, ie stimulate its excretion in the urine. Efficiency of canagliflozin and dapagliflozin in patients with type 2 diabetes mellitus has been demonstrated in controlled clinical trials. It is emphasized that their place in the treatment of diabetes mellitus should be determined by the results of further clinical and pharmacoepidemiological studies.

全文:

受限制的访问

作者简介

E. Ushkalova

Email: eushk@yandex.ru

参考

  1. Hardman TC, Dubrey SW. Development and Potential Role of Type-2 Sodium-Glucose Transporter Inhibitors for Management of Type 2 Diabetes. Diabetes Ther 2011;2(3):133-45.
  2. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-77.
  3. Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8.
  4. Moe OW, Wright SH, Palacin M. Renal handling of organic solutes. In: Brenner BM, ed. Brenner and Rector's The Kidney. 8th edition. Philadelphia: Saunders Elsevier, 2008:214-47.
  5. О-арилглюкозидные ингибиторы SGLT2 и способ их применения. Патент РФ № 2269540 (2006.02.10).
  6. Sabino-Silva R, Mori RC, David-Silva A, et al. The Na(+)/glucose cotransporters: from genes to therapy. Braz J Med Biol Res 2010;43(11):1019-26.
  7. Ehrenkranz RRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8.
  8. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-26.
  9. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-29.
  10. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-49.
  11. Macdonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010;12:1004-12.
  12. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510-16.
  13. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405-14.
  14. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012;32(1):80-94.
  15. United States Food and Drug Administration. FDA briefing document: NDA 202293 dapagliflozin tablets, 5 and 10 mg sponsor: Bristol-Myers Squibb.http://www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/drugs/ndocrinologicandMetabolicDrugsAdvisoryCommittee/ ucm262994.pdf
  16. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011;10(9):645-46.
  17. European Medicine's Agency. Summary of opinion: Forziga. http://www.ema.europa.eu/docs/ en_GB/document_library/Summary_of_opin-ion_-_Initial_authorisation/human/002322/ WC500125684.pdf
  18. INVOKANA™ [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2013.
  19. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 1995;2013;41(2):72-84.
  20. Yale J-F, Bakris G, Figueroa K, et al. Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor, Improves Glycemia and is Well Tolerated in Type 2 Diabetes Mellitus (T2DM) Subjects With Moderate Renal Impairment http:// www.abstractsonline.com/Plan/ViewAbstract. aspx?sKey=b266eaf6-c060-450a-9a54-ae244aae03af&cKey=062eb968-9ab7-4c0d-baa7-7272b7db6a6d&mKey=%7b0F70410F-8DF3-49F5-A63D-3165359F5371%7d
  21. Babu A. Canagliflozin for the treatment of type 2 diabetes. Drugs Today (Barc) 2013; 49(6):363-76.
  22. Nisly SA, Kolanczyk DM, Walton AM. Canagliflozin, a new sodium-glucose (SGLT2). Однако место этих препаратов в лечении СД2 должны определить результаты будущих клинических и фармакоэпидемиологических исследований. cotransporter 2 inhibitor, in the treatment of diabetes.Am J Health Syst Pharm 2013;70(4): 311-19.
  23. Gross JL, Schernthaner G, Fu M, et al. Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared with Sitagliptin in Patients with Type 2 Diabetes On Metformin Plus Sulfonylurea. http://www. abstractsonline. com/Plan/ViewAbstract. aspx?sKey=b266eaf6-c060-450a-9a54-ae244aae03af&cKey=0fb4f41e-05c7-4d2e-8707-eecb5716be63&mKey=%7b0F70410F-8DF3-49F5-A63D-3165359F5371%7d
  24. Cefalu W, Leiter LA, Niskanen L, et al. Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared With Glimepiride in Patients with Type 2 Diabetes on Background Metformin. http://www. abstractsonline. com/Plan/ViewAbstract. aspx?sKey=b266eaf6-c060-450a-9a54-ae244aae03af&cKey=33145c27-7078-4570-9094-553cc24b9c50&mKey=%7b0F70410F-8DF3-49F5-A63D-3165359F5371%7d
  25. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013;9(6):763-75.
  26. Experts Express Mixed Thoughts on Canagliflozin Approval. Medscape Medical News. Apr 18, 2013 http://www.medscape.com/viewarticle/782712
  27. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013;166(2): 217-23.
  28. FDA Approves Canagliflozin, a First-in-Class Diabetes Drug. Medscape. Mar 29, 2013.http:// www.medscape.com/viewarticle/781709
  29. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:313-27.
  30. Diamant M, Morsink LM.SGLT2 inhibitors for diabetes: turning symptoms into therapy. Lancet. 2013 Jul 11 [Epub ahead of print].

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##